This new application is submitted to initiate a Clinical Research Education for Drug Abuse Professionals (CREDAP) training program at Baylor College of Medicine, based on the successful CREDAP that was previously sited at UCLA. The overarching goal is to provide a coordinated, sustainable infrastructure of dedicated education and training that will produce independent healthcare professionals capable of conducting and disseminating clinical research pertaining to drug dependence and its treatment. This extensively revised application features an expansion of available mentors and research opportunities to include Pre-Clinical Human Pharmacology and Medications Testing (Drs. Newton, De La Garza), Brain Imaging and Cognitive Neuroscience (Drs. Moeller, Lane, and Steinberg), Neurogenetics (Dr. Nielson), Neurochemical Correlates of Addiction (Dr. Little) and Clinical Trials Research (Dr. Kosten). In addition, the program includes more extensive mechanisms of ensuring accountability of both faculty and trainees with the goal of consistently producing trainees that are able to successfully compete for funding.
The specific aims of the program are: 1. to provide trainees with a comprehensive understanding of drug abuse research and clinical practice, entailing interdisciplinary clinical research education and training lasting two years at post-doctoral level under the guidance of preceptors. 2. To educate trainees to have full competence in using experimental techniques appropriate for the investigation of drug abuse, emphasizing advanced technologies, procedural reliability, and validity. 3. To encourage trainees to investigate a defined clinical research issue in drug abuse, with a focus on clinical trials research, starting them on a course of clinical research that will continue beyond the 2-year program. 4. To prepare trainees to become productive clinical researchers by teaching them to prepare manuscripts reporting research results that merit publication in peer-reviewed, high-quality biomedical journals, to write and submit grant applications to the NIH, and to become part of national research communities by attending meetings, seminars, and symposia where they may present research, gain new knowledge, and forge new collaborations. 5. To increase diversity in the training program through identifying and soliciting applications from promising candidates from underrepresented populations, including racial/ethnic groups and women. 6. To further develop and refine the program through formal evaluation efforts that provide input on areas that can be improved.
This revised application is submitted for continuation of the Clinical Research Education for Drug Abuse Professionals (CREDAP) training program. The overarching goal is to provide a coordinated, sustainable infrastructure of dedicated education and training that will produce independent healthcare professionals capable of conducting and disseminating clinical research pertaining to drug dependence and its treatment.
|Haile, C N; Murrough, J W; Iosifescu, D V et al. (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:331-6|
|Mahoney 3rd, James J; De La Garza 2nd, Richard; Jackson, Brian J et al. (2014) The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res 219:367-71|
|Mahoney 3rd, James J; Kalechstein, Ari D; Verrico, Christopher D et al. (2014) Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry 50:137-42|
|De La Garza 2nd, R; Galloway, G P; Newton, T F et al. (2014) Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine. Prog Neuropsychopharmacol Biol Psychiatry 50:44-52|
|Verrico, Christopher D; Mahoney 3rd, James J; Thompson-Lake, Daisy G Y et al. (2014) Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 17:223-33|
|Haile, Colin N; De La Garza 2nd, Richard; Mahoney 3rd, James J et al. (2013) Effects of methamphetamine on the noradrenergic activity biomarker salivary alpha-amylase. Drug Alcohol Depend 133:759-62|
|Verrico, Christopher D; Haile, Colin N; Newton, Thomas F et al. (2013) Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opin Investig Drugs 22:1549-68|
|Volk, David W; Siegel, Benjamin I; Verrico, Christopher D et al. (2013) Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. Schizophr Res 147:53-57|
|Shorter, D; Lindsay, J A; Kosten, T R (2013) The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug Alcohol Depend 131:66-70|
|Shorter, D; Nielsen, D A; Huang, W et al. (2013) Pharmacogenetic randomized trial for cocaine abuse: disulfiram and *1A-adrenoceptor gene variation. Eur Neuropsychopharmacol 23:1401-7|
Showing the most recent 10 out of 15 publications